1887

Abstract

Histone deactylase inhibitors (HDACi) are common chemotherapeutic agents that stimulate Epstein–Barr virus (EBV) reactivation; the detailed mechanism remains obscure. In this study, it is demonstrated that PKC is required for induction of the EBV lytic cycle by HDACi. Inhibition of PKC abrogates HDACi-mediated transcriptional activation of the Zta promoter and downstream lytic gene expression. Nuclear translocation of PKC is observed following HDACi stimulation and its overexpression leads to progression of the EBV lytic cycle. Our study suggests that PKC is a crucial mediator of EBV reactivation and provides a novel insight to study the regulation of the EBV lytic cycle.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83533-0
2008-04-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/4/878.html?itemId=/content/journal/jgv/10.1099/vir.0.83533-0&mimeType=html&fmt=ahah

References

  1. Chang L. K., Liu S. T. 2000; Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation. Nucleic Acids Res 28:3918–3925 [CrossRef]
    [Google Scholar]
  2. Chang Y., Chang S. S., Lee H. H., Doong S. L., Takada K., Tsai C. H. 2004a; Inhibition of the Epstein–Barr virus lytic cycle by Zta-targeted RNA interference. J Gen Virol 85:1371–1379 [CrossRef]
    [Google Scholar]
  3. Chang Y., Lee H. H., Chang S. S., Hsu T. Y., Wang P. W., Chang Y. S., Takada K., Tsai C. H. 2004b; Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta. J Virol 78:13028–13036 [CrossRef]
    [Google Scholar]
  4. Chang Y., Lee H. H., Chen Y. T., Lu J., Wu S. Y., Chen C. W., Takada K., Tsai C. H. 2006; Induction of the early growth response 1 gene by Epstein-Barr virus lytic transactivator Zta. J Virol 80:7748–7755 [CrossRef]
    [Google Scholar]
  5. Choi H. S., Lee J. H., Park J. G., Lee Y. I. 2002; Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex. Biochem Biophys Res Commun 296:1005–1012 [CrossRef]
    [Google Scholar]
  6. Chua H. H., Lee H. H., Chang S. S., Lu C. C., Yeh T. H., Hsu T. Y., Cheng T. H., Cheng J. T., Chen M. R. other authors 2007; Role of the TSG101 gene in Epstein-Barr virus late gene transcription. J Virol 81:2459–2471 [CrossRef]
    [Google Scholar]
  7. Constantinescu S. N., Cernescu C. D., Popescu L. M. 1991; Effects of protein kinase C inhibitors on viral entry and infectivity. FEBS Lett 292:31–33 [CrossRef]
    [Google Scholar]
  8. Daibata M., Speck S. H., Mulder C., Sairenji T. 1994; Regulation of the BZLF1 promoter of Epstein-Barr virus by second messengers in anti-immunoglobulin-treated B cells. Virology 198:446–454 [CrossRef]
    [Google Scholar]
  9. Davie J. R. 2003; Inhibition of histone deacetylase activity by butyrate. J Nutr 133:2485S–2493S
    [Google Scholar]
  10. Davies A. H., Grand R. J., Evans F. J., Rickinson A. B. 1991; Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C. J Virol 65:6838–6844
    [Google Scholar]
  11. Deutsch E., Cohen A., Kazimirsky G., Dovrat S., Rubinfeld H., Brodie C., Sarid R. 2004; Role of protein kinase C delta in reactivation of Kaposi'; s sarcoma-associated herpesvirus. J Virol 78:10187–10192 [CrossRef]
    [Google Scholar]
  12. Emoto Y., Manome Y., Meinhardt G., Kisaki H., Kharbanda S., Robertson M., Ghayur T., Wong W. W., Kamen R. other authors 1995; Proteolytic activation of protein kinase C δ by an ICE-like protease in apoptotic cells. EMBO J 14:6148–6156
    [Google Scholar]
  13. Eun D. W., Ahn S. H., You J. S., Park J. W., Lee E. K., Lee H. N., Kang G. M., Lee J. C., Choi W. S. other authors 2007; PKCϵ is essential for gelsolin expression by histone deacetylase inhibitor apicidin in human cervix cancer cells. Biochem Biophys Res Commun 354:769–775 [CrossRef]
    [Google Scholar]
  14. Feng W. H., Kenney S. C. 2006; Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 66:8762–8769 [CrossRef]
    [Google Scholar]
  15. Feng W. H., Israel B., Raab-Traub N., Busson P., Kenney S. C. 2002; Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 62:1920–1926
    [Google Scholar]
  16. House C., Kemp B. E. 1987; Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science 238:1726–1728 [CrossRef]
    [Google Scholar]
  17. Ju R., Muller M. T. 2003; Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res 63:2891–2897
    [Google Scholar]
  18. Kieff E., Rickinson A. B. 2001; Epstein-Barr virus and its replication. In Fields Virology , 4th edn. pp 2511–2573Edited by Knipe D. M., Howley. Philadelphia, PA: Lippincott Williams & Wilkins;
    [Google Scholar]
  19. Kim Y. K., Han J. W., Woo Y. N., Chun J. K., Yoo J. Y., Cho E. J., Hong S., Lee H. Y., Lee Y. W. other authors 2003; Expression of p21(WAF1/Cip1) through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinase-PKC epsilon signaling pathway. Oncogene 22:6023–6031 [CrossRef]
    [Google Scholar]
  20. Kim S., Kang J. K., Kim Y. K., Seo D. W., Ahn S. H., Lee J. C., Lee C. H., You J. S., Cho E. J. other authors 2006; Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites. Biochem Biophys Res Commun 342:1168–1173 [CrossRef]
    [Google Scholar]
  21. Kim Y. H., Lim J. H., Lee T. J., Park J. W., Kwon T. K. 2007; Expression of cyclin D3 through Sp1 sites by histone deacetylase inhibitors is mediated with protein kinase C- δ (PKC- δ ) signal pathway. J Cell Biochem 101:987–995 [CrossRef]
    [Google Scholar]
  22. Luka J., Kallin B., Klein G. 1979; Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228–231 [CrossRef]
    [Google Scholar]
  23. Marks P. A., Dokmanovic M. 2005; Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14:1497–1511 [CrossRef]
    [Google Scholar]
  24. Naranatt P. P., Akula S. M., Zien C. A., Krishnan H. H., Chandran B. 2003; Kaposi'; s sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC- ζ -MEK-ERK signaling pathway in target cells early during infection: implications for infectivity. J Virol 77:1524–1539 [CrossRef]
    [Google Scholar]
  25. Newton A. C. 1997; Regulation of protein kinase C. Curr Opin Cell Biol 9:161–167 [CrossRef]
    [Google Scholar]
  26. Schuster C., Chasserot-Golaz S., Beck G. 1991; Activation of Epstein-Barr virus promoters by a growth-factor and a glucocorticoid. FEBS Lett 284:82–86 [CrossRef]
    [Google Scholar]
  27. Shirai Y., Saito N. 2002; Activation mechanisms of protein kinase C: maturation, catalytic activation, and targeting. J Biochem (Tokyo) 132:663–668 [CrossRef]
    [Google Scholar]
  28. Sieczkarski S. B., Brown H. A., Whittaker G. R. 2003; Role of protein kinase C β II in influenza virus entry via late endosomes. J Virol 77:460–469 [CrossRef]
    [Google Scholar]
  29. Steinberg S. F. 2004; Distinctive activation mechanisms and functions for protein kinase C δ . Biochem J 384:449–459 [CrossRef]
    [Google Scholar]
  30. Storz P., Doppler H., Toker A. 2004; Protein kinase C δ selectively regulates protein kinase D-dependent activation of NF- κ B in oxidative stress signaling. Mol Cell Biol 24:2614–2626 [CrossRef]
    [Google Scholar]
  31. Yamamoto T., Matsuzaki H., Kamada S., Ono Y., Kikkawa U. 2006; Biochemical assays for multiple activation states of protein kinase C. Nat Protoc 1:2791–2795
    [Google Scholar]
  32. Ye J., Shedd D., Miller G. 2005; An Sp1 response element in the Kaposi'; s sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle induction by butyrate. J Virol 79:1397–1408 [CrossRef]
    [Google Scholar]
  33. Yokota T., Matsuzaki Y., Miyazawa K., Zindy F., Roussel M. F., Sakai T. 2004; Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene 23:5340–5349 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83533-0
Loading
/content/journal/jgv/10.1099/vir.0.83533-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error